At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
Surgery is the primary treatment for skin cancer. Patients' perception of the scar following surgery for facial skin cancer may significantly influence their satisfaction with their care. The purpose of this study is to assess patients' satisfaction with the appearance of their face and scar after skin cancer surgery at Memorial Sloan Kettering Cancer Center (MSK), as well as their quality of life after the surgery.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
If you take part in this study, you will be randomly assigned to receive one of these therapies:
- A Study to See if Anti-BCMA CAR T-Cell Therapy Can Be Made from People with Multiple Myeloma Who Have Had a Stem Cell Transplant
Full Title Feasibility Trial of Autologous Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for Multiple Myeloma Patients Status Post Hematopoietic Cell Transplantation
Purpose
With CAR T-cell therapy, some of a patient’s own T cells (a type of white blood cell) are removed and genetically modified in a laboratory to recognize their own cancer cells. The modified T cells, known as CAR T cells, are then returned to the patient to find and kill cancer cells throughout the body. This approach is a form of immunotherapy.
The purpose of this study is to see if the quality of T cells used to make commercial CAR T-cell therapies affects how the CAR T cell prevents cancer from coming back in people with recurrent or persistent multiple myeloma who have had a stem cell transplant. The quality of T cells is dependent on when they were collected. T cells are considered to be high-quality when collected from stem cells (special cells that can develop into different cell types) around the time of the cancer diagnosis and/or from the donor’s cells before chemotherapy treatment.
Patients in this study will receive commercial CAR T cells directed against the BCMA protein on myeloma cells as part of their standard treatment. Researchers will collect samples of the patients’ blood and test the liquid part of the soft tissue inside their bones (bone marrow aspirate) before and after they receive CAR T cells. The investigators will then see how the quality of the T cells in these samples affects the way their cancers respond to CAR T cell treatment.
Who Can Join
To be eligible for this study, patients must meet several requirements, including:
- Participants in this study must have multiple myeloma that has come back or persists despite treatment with four or more prior therapies that included a stem cell transplant.
- Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
- This study is for people age 18 and older.
For more information and to ask about eligibility for this study, please contact the office of Dr. Gunjan Shah at 212-639-8356.
Protocol
22-118Phase
Phase II (phase 2)Disease Status
Relapsed or RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT05393804ClinicalTrials.gov
-
Researchers are doing this study to see how well COM701 immunotherapy works when used as maintenance therapy for ovarian cancer. Maintenance therapy helps keep cancer from growing again after it shrank or stopped growing following earlier treatment.
-
Researchers want to see if combining etentamig (ABBV-383) with iberdomide is a safe treatment for multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing after treatment. The researchers will assess different doses of these drugs to find the best dose for patients.
-
The goal of this study is to find the best dose of lenalidomide that can be given together with the usual combination chemotherapy in adults with HTLV-associated T-cell leukemia-lymphoma. The usual chemotherapy consists of the drugs etoposide, prednisone, vincristine sulfate (Oncovin), cyclophosphamide, and doxorubicin hydrochloride (hydroxydaunorubicin hydrochloride) and is known as EPOCH. Lenalidomide may help shrink or slow the growth of adult T-cell leukemia-lymphoma.
-
Researchers want to find the best dose of REM-422 to use in people with advanced adenoid cystic cancer (ACC). ACC most commonly starts in the salivary glands. The people in this study have ACC that has spread and may high levels of a protein called MYB. This protein can cause cancer cells to grow.
-
In this study, researchers are comparing the effectiveness bevacizumab plus osimertinib versus osimertinib alone as initial treatment for patients with stage IIIB-IV non-small cell lung cancer that contains a mutation in a gene called EGFR.
-
After endometrial cancer surgery, there is a risk that the cancer will come back. Combining a shorter course of radiation treatment with chemotherapy may decrease the chance of endometrial cancer recurring.